Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
| Revenue (TTM) | $85.72M |
| Gross Profit (TTM) | $45.44M |
| EBITDA | $-35.36M |
| Operating Margin | 41.20% |
| Return on Equity | -837.00% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $0.25 |
| Book Value | $0.12 |
| Price-to-Book | 61.05 |
| Price-to-Sales (TTM) | 32.37 |
| EV/Revenue | 31.74 |
| EV/EBITDA | -3.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 6323.00% |
| Shares Outstanding | $356.51M |
| Float | $194.60M |
| % Insiders | 12.64% |
| % Institutions | 72.84% |
Volatility is currently expanding
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.
Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGEN and any ticker you trade — then tracks every position and per-strategy win rate.
